Targeted kinase selectivity from kinase profiling data.

Kinase selectivity plays a major role in the design strategy of lead series and in the ultimate success of kinase drug discovery programs. Although profiling compounds against a large panel of protein kinases has become a standard part of modern drug discovery, data accumulated from these kinase panels may be underutilized for new kinase projects. We present a method that can be used to optimize the selectivity profile of a compound using historical kinase profiling data. This method proposes chemical transformations based on pairs of very similar compounds, which are both active against a desired target kinase and differ in activity against another kinase. We show that these transformations are transferable across scaffolds, thus making this tool valuable to exploit kinase profiling data for unrelated series of compounds.

[1]  Xin Xu,et al.  Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. , 2010, Arthritis and rheumatism.

[2]  J. Bajorath,et al.  Chemical Substitutions That Introduce Activity Cliffs Across Different Compound Classes and Biological Targets , 2010, J. Chem. Inf. Model..

[3]  Charles Eigenbrot,et al.  A new regulatory switch in a JAK protein kinase , 2011, Proteins.

[4]  J. Kuriyan,et al.  c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. , 2007, Structure.

[5]  P. Hajduk,et al.  Navigating the kinome. , 2011, Nature chemical biology.

[6]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[7]  Daniel Rauh,et al.  Proteus in the World of Proteins: Conformational Changes in Protein Kinases , 2010, Archiv der Pharmazie.

[8]  A. Tefferi,et al.  CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients , 2009, Leukemia.

[9]  B. Klebansky,et al.  Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3. , 2010, Bioorganic & medicinal chemistry letters.

[10]  P. Caron,et al.  Classifying protein kinase structures guides use of ligand‐selectivity profiles to predict inactive conformations: Structure of lck/imatinib complex , 2007, Proteins.

[11]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[12]  David S. Nirschl,et al.  Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3. , 2011, Bioorganic & medicinal chemistry letters.

[13]  Ken Garber,et al.  Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis , 2011, Nature Biotechnology.

[14]  Rajarshi Guha,et al.  Structure—Activity Landscape Index: Identifying and Quantifying Activity Cliffs. , 2008 .

[15]  Andrew G. Leach,et al.  Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure. , 2006, Journal of medicinal chemistry.

[16]  A. Kuglstatter,et al.  Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. , 2010, Journal of medicinal chemistry.

[17]  Visakan Kadirkamanathan,et al.  Lead Optimization Using Matched Molecular Pairs: Inclusion of Contextual Information for Enhanced Prediction of hERG Inhibition, Solubility, and Lipophilicity , 2010, J. Chem. Inf. Model..